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Abstract
Background: Leishmania (Viannia) parasites present particular challenges, as human and murine immune responses to
infection are distinct from other Leishmania species, indicating a unique interaction with the host. Further, vaccination
studies utilizing small animal models indicate that modalities and antigens that prevent infection by other Leishmania
species are generally not protective.
Methodology: Using a newly developed mouse model of chronic L. (Viannia) panamensis infection and the heterologous
DNA prime – modified vaccinia virus Ankara (MVA) boost vaccination modality, we examined whether the conserved
vaccine candidate antigen tryparedoxin peroxidase (TRYP) could provide protection against infection/disease.
Results: Heterologous prime – boost (DNA/MVA) vaccination utilizing TRYP antigen can provide protection against disease
caused by L. (V.) panamensis. However, protection is dependent on modulating the innate immune response using the
TLR1/2 agonist Pam3CSK4 during DNA priming. Prime-boost vaccination using DNA alone fails to protect. Prior to infection
protectively vaccinated mice exhibit augmented CD4 and CD8 IFNc and memory responses as well as decreased IL-10 and
IL-13 responses. IL-13 and IL-10 have been shown to be independently critical for disease in this model. CD8 T cells have an
essential role in mediating host defense, as CD8 depletion reversed protection in the vaccinated mice; vaccinated mice
depleted of CD4 T cells remained protected. Hence, vaccine-induced protection is dependent upon TLR1/2 activation
instructing the generation of antigen specific CD8 cells and restricting IL-13 and IL-10 responses.
Conclusions: Given the general effectiveness of prime-boost vaccination, the recalcitrance of Leishmania (Viannia) to
vaccine approaches effective against other species of Leishmania is again evident. However, prime-boost vaccination
modality can with modulation induce protective responses, indicating that the delivery system is critical. Moreover, these
results suggest that CD8 T cells should be targeted for the development of a vaccine against infection caused by Leishmania
(Viannia) parasites. Further, TLR1/2 modulation may be useful in vaccines where CD8 T cell responses are critical.
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Introduction
Traditionally, vaccination against cutaneous leishmaniasis (CL)
has involved leishmanization (inoculation of live Leishmania), which
has been practiced throughout the Middle East and was employed
in government sponsored vaccination programs both in Israel and
Russia. However, safety and standardization issues discouraged
further use of live vaccination [1,2]. Subsequently, killed Leishmania
promastigotes have been examined with some but limited efficacy
in clinical trials [3,4]. Consequently, leishmaniasis vaccine efforts
have focused on the use of live attenuated vaccines [5,6] and also
defined molecular vaccines and delivery systems [7].
An optimal vaccine against cutaneous leishmaniasis would
consistently provide protection against the various disease-causing
species. However, studies indicate that distinct Leishmania species
elicit different responses in their hosts, suggesting that a uniform
approach might be challenging. Although a Th1-like response is
considered to lead to disease resolution, the mechanisms contrib-
uting to protection across the species are not well characterized/
understood. In particular, the Leishmania (Viannia) subgenus is
phylogenetically divergent from the Leishmania (Leishmania) subgenus
[8,9,10]. Members of the L. (Viannia) subgenus can generate a
hyperinflammatory response that fails to resolve [11,12,13,14,
15,16]. L. (V).panamensis elicits a mixed Th1/Th2 and non-resolving
hyperinflammatory response to infection in humans [17,18].
Consistent with this, vaccine studies attempting to demonstrate
immunological protection against L. (Viannia) parasites [19,20,21]
using a murine model, have met with limited success. Salay et al.
www.plosntds.org 1 June 2011 | Volume 5 | Issue 6 | e1204[19] tested four different highly conserved leishmanial antigens
(DNA or recombinant protein) along with adjuvants that have
protected against infection with other species causing CL (L.
mexicana, L. amazonensis, L. major). However, strong antigen-specific
IFNc production by immunized mice failed to translate into
protection against L. (Viannia) braziliensis infection. As a result this
study suggested investigation of alternate immunization strategies
to protect against L. (Viannia) parasites. Similarly, antigens
demonstrated to protect against visceral leishmaniasis [21] failed
to protect against L. (Viannia) braziliensis. Recently, partial
protection was [20] demonstrated against L.(V.) braziliensis by
utilizing an attenuated centrin-deficient L. donovani strain. Taken as
a whole these studies might suggest that defined antigens may not
provide protection against L. (Viannia). However, vaccine delivery
systems are critical to determining the elicited immune response
and therefore can determine protection provided for an antigen.
In particular, as the mechanisms involved in disease resolution for
L. (Viannia) are not well understood, further investigation of
delivery systems/antigens is warranted and may ultimately provide
insight into immune mechanisms leading to healing. Hence we
explored other immunization methods to induce protection
against L. (V.) panamensis, using a newly developed murine model
for chronic disease [22].
Herein we report for the first time that heterologous prime
(DNA) -boost (modified vaccinia virus Ankara = MVA) modality
using the single antigen tryparedoxin peroxidase (TRYP) and
including the TLR1/2 agonist N-palmitoyl-S-[2,3-bis(palmitoy-
loxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-
lysyl-[S]-lysine (Pam3CSK4) as adjuvant during DNA priming is
effective in achieving protection against L.(V.) panamensis. Mark-
edly, prime boost immunization in the absence of Pam3CSK4 did
not elicit protection thereby implicating a strategic role for
Pam3CSK4 in achieving protection. Pam3CSK4 appears to direct
heightened CD4 and CD8 T memory cell responses and reduced
levels of IL-10 and IL-13, which ultimately results in significant
protection against L.(V.) panamensis. Furthermore CD8 cells, but
interestingly not CD4 T cells, are crucial in mediating the
protection induced, indicating that CD8 T cell responses may be
critical for vaccine development against L. (Viannia) parasites.
Materials and Methods
Leishmania culture and infection
L. (V.) panamensis was grown and cultured into infective stage
parasites as described previously [22]. Briefly L. (V.) panamensis was
grown in Schneider’s Medium supplemented with 20% heat
inactivated FCS and 17.5 mg/mL gentamycin (GIBCO BRL).
Promastigotes were grown at 22uC. Live late stationary phase (15–
21 days in culture) promastigotes were harvested for infection
using a step percoll gradient (Sigma Chemical Co.) in PBS
containing 20 mM EDTA. Washed parasites (5610
4) were used to
infect mice in the top of the right hind foot.
Animals
Female BALB/c mice (5 to 6 weeks old) were purchased from
the NCI. All mice were housed in Yale University School of
Medicine facilities, which are American Association for Accred-
itation of Laboratory Animal Care (AAALAC) accredited and
USDA registered animal facilities. The experiments were
approved by Yale University Committee on Use and Care of
Animals (Assurance number A3230-01).
Plasmids, recombinant proteins, and vaccinia virus
TRYP and p36 (LACK) genes were cloned into pVAX
(Invitrogen, CA) and pCI-neo (Promega, WI) vectors respectively.
Plasmids were purified using Qiagen Endofree Plasmid Giga kit
(Qiagen, CA). Empty plasmid was used for the controls. Plasmid
preparations were tested for endotoxin by Limulus Amebocyte
Lysate test (Lonza, MD); less than 0.1 ng LPS per 100 mgo f
plasmid was present in preparations employed for vaccination.
The p36 and TRYP recombinant proteins were expressed using a
histidine-tag construct that was cloned into pRSET A vector
kindly provided by Dr. Larraga (Centro de Investigaciones
Biolo ´gicas, Spain) and pET-15b vector, respectively. Recombinant
protein was purified using PrepEase Histidine-Tagged Protein
Purification kit (USB, OH) and endotoxin was removed as
described [23]. Coomassie blue staining of SDS-PAGE analysis
of recombinant antigen was used to determine protein purity.
Vaccinia virus Ankara (MVA) expressing TRYP and LACK were
prepared as previously described [24,25].
Vaccination and immunodepletion studies
For adjuvant evaluation, mice (3/group) received two intra
dermal injections of p36 DNA (100 ug in 100 ul) per vaccination
with or without adjuvants (a-GalCer (1 ug), LPS (10 ug), CpG
(50 ug), Pam3CSK4 (10 ug), MALP-2 (0.5 ug)). After an interval
of 3 weeks, mice were boosted using the same DNA-adjuvant
combination. Splenocytes from the vaccinated mice were evalu-
ated by in vitro cytokine production 4 weeks after the final
immunization. This experiment was done twice and 3 mice per
group were sufficient to achieve statistical significance and evalu-
ation of data.
In the case of DNA-vaccinia virus (MVA) prime-boost vacci-
nation, 2 weeks after the priming immunization with TRY-
P(100 ug/100 ul) 6 Pam3CSK4, mice (8 to 10/group) were
boosted intraperitoneally with 3610
6 PFU per mouse of MVA-
TRYP. This was followed by infection with 5610
4 late stationary
phase L. (V.) panamensis promastigotes 6 weeks after the MVA
boost. Lesion development was monitored by measuring the
thickness of the infected and uninfected feet using a dial gauge
Author Summary
Leishmania (Viannia) are the predominant agents of
leishmaniasis in Latin America. Given the fact that
leishmaniasis is a zoonosis, eradication is unlikely; a
vaccine could provide effective prevention of disease.
However, these parasites present a challenge and we do
not fully understand what elements of the host immune
defense prevent disease. We examined the ability of
vaccination to protect against L. (Viannia) infection using
the highly immunogenic heterologous prime-boost (DNA-
modified vaccinia virus) modality and a single Leishmania
antigen (TRYP). Although this mode of vaccination can
induce protection against other leishmaniases (cutaneous,
visceral), no protection was observed against L. (V.)
panamensis. However, we found that if the vaccination
was modified and the innate immune response was
activated through Toll-like receptor1/2(TLR1/2) during
the DNA priming, vaccinated mice were protected.
Protection was dependent on CD8 T cells. Vaccinated
mice had higher CD8 T cell responses and decreased levels
of cytokines known to promote infection. Given the long-
term persistence of CD8 T cell memory, these findings are
encouraging for vaccine development. Further, these
results suggest that modulation of TLR1/2 signaling could
improve the efficacy of DNA-based vaccines, especially
where CD8 T cell activation is critical, thereby contributing
to effective and affordable anti parasitic vaccines.
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foot and draining lymph node (DLN) were determined by limiting
dilution analysis as described previously [26,27]. As parasite
burden changes in the infected foot and associated DLN were
comparable comparative in initial experiments, parasite burdens
were determined only in the infected feet of the immunodepleted
mice. For depletion of CD4 or CD8 cells, immunized mice were
injected intraperitoneally with 100 mg of anti-CD4 (GK1.5) or
anti-CD8 (53-5-43) antibody (eBioscience, CA) at -3 and -1 day
before infection. Flow cytometry indicated that more than 95% of
the target cell population was depleted. Pre-challenge immunoas-
says were carried out 12 weeks after the MVA boost in TRYP
immunized mice.
Cytokine, and proliferation analysis
DLN cells and splenocytes were plated at 5610
6/ml in RPMI
(10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml peni-
cillin, 100 mg/ml streptomycin, and 50 mM b-mercaptoethanol) in
96 or 24 well plates. The cells were then stimulated with recom-
fbinant TRYP (5 mg/ml), recombinant LACK/p36 (5 mg/ml), solu-
ble leishmania antigen (SLA; equivalent to 5610
6 parasites/ml) or
left unstimulated for 72 hours. Supernatants were collected and
analyzed for IFNc, IL-10, and IL-13 using paired antibodies from
BD Biosciences (CA) and R&D systems (MN). For flow cytometry,
brefeldin A (BD Biosciences, CA) at 1 ug/ml was added to
stimulated splenocytes during the last 4 hours, cells were surface
stained with T cell markers, fixed with 2% paraformaldehyde and
permeabilized with 0.05% saponin followed by intracellular
staining. Isotype control antibodies were IgG1-PE-Cy7 and IgG1-
PE. Forward and side scatter were used to determine lymphocytes
followed by gating on CD4+ or CD8+ cells. Integrated mean
fluorescence intensity (iMFI) was calculated by the following
formula: iMFI = MFI x frequency [28]. Data were acquired using
an LSRll(BD Biosciences, CA)and analyzed usingFlowJo (Treestar
Inc., Oregon).
For proliferation analyses to evaluate memory responses, splenic
lymphocytes were labeled with 5 mM carboxyfluorescein succini-
midyl ester (CFSE) at 3 months/12 weeks after the final MVA
boost; cells were then placed in 96 well plates at 5610
6/ml in
RPMI (10% fetal bovine serum, L-glutamine, penicillin/strepto-
mycin, and b-mercaptoethanol), and stimulated with recombinant
TRYP (5 mg/ml) for 3 days. Following surface staining with CD4
and CD8 antibodies, FACS analysis was done as described above
to measure proliferation by dilution of CFSE dye. Unlabeled cells
and unstimulated CFSE-labeled cells were used as controls.
Antibodies and reagents
Antibodies (CD4-Pacific blue, CD8-APC, IFNc-PE-Cy7, IL-13-
PE, IgG1-PE-Cy7, IgG1-PE, affinity purified CD4 (L3T4), and
CD8 (Ly-2)) were purchased from BD Biosciences (CA) and
eBiosciences (CA). Pam3CSK4, CpG (ODN1826), ultra pure E.
coli lipopolysaccharide (LPS), and MALP-2 were purchased from
Invivogen Inc (CA). a-galactosyl-ceramide was obtained from
Biomol International (PA).
Ethics Statement
All experiments were approved Yale University Committee on
Use and Care of Animals (Assurance number A3230-01).
Statistics
Student’s t test was used to determine p values indicating
statistical differences for all experiments and p,0.05 was con-
sidered statistically significant.
Results
Adjuvant modulation of the immune response to antigen
induced by DNA vaccination
Initially, we sought to examine the effects of adjuvants on the
immune response induced during DNA vaccination, as it is known
that priming is critical [29,30,31,32], to the overall response
induced in heterologous prime-boost vaccination. Compounds
known to activate NK-T cells (alpha-galactosyl ceramide
(a-Galcer)) [33], as well as TLR ligands TLR9 (CpG [34]),
TLR2/6 (MALP-2 [35]), TLR4 (LPS [36]), and TLR2/
1(Pam3CSK4 [37]) were chosen as potential adjuvants for DNA
vaccination, using the Leishmania homologue of receptors for
activated C-kinases (LACK)/p36 antigen. The adjuvants (Figure
S1A) were evaluated on the basis of their ability to enhance the
production of antigen specific IFNc relative to IL-10 in DNA
immunized mice, as better protection against cutaneous leishman-
iasis has been associated with a higher ratio of IFNc to IL-10 [24]
and disease exacerbation of L. (Viannia) has been related to IL-10
levels [38]. High IL-10 production was observed for MALP-2 and
LPS. The IFNc/IL-10 ranking was Pam3CSK4$ a-Gal-
Cer.CpG..LPS...MALP-2. Consequently, amongst the
adjuvants, Pam3CSK4 and a-GalCer appeared to induce a
potentially useful immune response.
Based on these results, Pam3CSK4 and a-GalCer were selected
to determine if a combination of Pam3CSK4 and/or a-GalCer,
which have distinct cellular targets, could act synergistically to
further enhance the immunogenicity of DNA-p36. In these
experiments (Figures S1B and S1C), IFNc, IL-13, and IL-10
responses to p36 were determined. Although a considerable
increase in the IFNc to IL-10 ratio was seen in response to
immunization with DNA-p36+ a-GalCer +Pam3CSK4, a-GalCer
alone induced increased levels of IL-13 (Figure S1C). As IL-13 has
been shown to play a critical role in determining progression of
non-healing pathogenesis of L. (V.) panamensis [22], Pam3CSK4
was selected as a potential adjuvant for use in a prime (DNA) boost
(vaccinia) immunization against murine L. (V.) panamensis infection.
To further evaluate the potential of Pam3CSK4 in DNA
priming, heterologous prime-boost immunization (Figure 1) using
the TRYP antigen was examined. Mice were immunized
intradermally with DNA-TRYP or DNA-TRYP together with
Pam3CSK4. Control mice received empty vector DNA. Two
weeks later, groups of the immunized mice were boosted with
vaccinia virus expressing the TRYP antigen (MVA-TRYP) or with
control vaccinia virus (MVA). Twelve weeks after the final
immunization, the immune responses of splenocytes from
immunized and non-immunized mice were analyzed. Mice
immunized with DNA-TRYP(Pam3CSK4)+MVA-TRYP pro-
duced increased levels of IFNc and granzyme B in response to
both TRYP and SLA when compared to mice immunized with
DNA- TRYP+MVA-TRYP or DNA-TRYP (Figure 1). Further-
more, mice receiving Pam3CSK4 during priming also produced
significantly lower levels of antigen specific IL-13 and IL-10 when
compared to mice immunized with DNA-TRYP+MVA-TRYP.
Thus, DNA-TRYP(Pam3CSK4)+MVA-TRYP immunized mice
generated higher amounts of IFNc as well as reduced levels of IL-
13 and IL-10 in response to either TRYP or SLA antigen when
compared to mice immunized with DNA-TRYP alone. Hence the
activation of TLR1/2(Pam3CSK4) during DNA priming (as found
for DNA vaccination alone) appears to promote the down-
regulation of IL-13 and IL-10 responses and concurrent up-
regulation of Th1 cytokines in heterologous prime-boost vaccina-
tion, leading to higher IFNc to IL-13 and IFNc to IL-10 ratios.
Vaccine Induced Defense against L. (V.) panamensis
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specific CD8 and CD4 T cells in immunized mice
To further evaluate the effects of Pam3CSK4 on the deve-
lopment of specific long-term CD4 and CD8 T cell memory, the
proliferative responses to TRYP antigen were examined 12 weeks
after the MVA-TRYP boost. Splenic lymphocytes from immu-
nized mice were labeled with CFSE and then stimulated for 3 days
with recombinant TRYP protein. Increased proliferation of both
CD4 and CD8 cells (Figure 2A) was observed in DNA-
TRYP(Pam3CSK4)+MVA-TRYP immunized mice when com-
pared to the other vaccinated groups. Overall, the responses
observed (10–15% proliferating cells) were comparable to other
studies examining long-term memory [39,40,41]. The kinetics
indicated a heightened response (CD4 and CD8 T cells) after 3
days of stimulation for the cells from mice immunized with DNA-
TRYP(Pam3CSK4)+MVA-TRYP. As the number of proliferating
cells is expected to be in proportion to memory populations, these
results clearly indicate increased levels of both CD4 and CD8
memory cells as a consequence of vaccination using Pam3CSK4.
In particular, a higher increase in antigen specific CD8 cell
proliferation (5.4-fold) was observed in mice receiving DNA-
TRYP(Pam3CSK4)+MVA-TRYP in comparison to CD4 cells
(1.5-fold). These data suggest that although both CD4 and CD8
memory populations expand as a result of TLR1/2 ligation, a
selective effect on CD8 T cell populations occurs. Overall, these
data point to a more rapid and robust response and higher levels of
memory populations (CD4+ and CD8+) in mice receiving
Pam3CSK4 in comparison to those immunized with DNA-TRYP
alone.
The immunization with DNA-TRYP(Pam3CSK4)+ MVA-
TRYP resulted in a polarized Th1 immune response 12 weeks
after the final booster dose (Figure 1). Given that expansion of
both CD4 and CD8 memory cells (Figure 2A) was observed, it was
of interest to investigate the precise cellular components of this
immune response. FACS analysis of cells stimulated with
recombinant TRYP was carried out at twelve weeks after the
final immunization (Figure 2B). These results, consistent with
ELISA results, indicated that the frequency of CD4 and CD8 cells
producing IFNc were increased in DNA-TRYP(Pam3CSK4)
+MVA-TRYP immunized mice in comparison to the DNA-
TRYP+MVA-TRYP immunized mice. Notably a significantly
lower level of CD4 and CD8 T cells producing IL-13 was found.
Overall, the increased frequency of IFNc producing CD4 and
CD8 cells in DNA-TRYP(Pam3CSK4)+MVA-TRYP immunized
mice in comparison to the DNA-TRYP+MVA-TRYP immunized
mice or control groups were statistically different (Figure 2C).
Overall, these results suggest that TLR1/2 activation drives the
development of Th1/TC1-like responding T (CD4 and CD8)
cells. Consequently, the ligation of TLR9 (by bacterial CpG
sequences) together with TLR1/2 during priming appears to
preferentially enhance the generation of TRYP-specific memory T
cells, producing IFNc but also significantly less IL-13.
Protection against L.(V).panamensis infection requires
TLR1/2 activation during priming
Given the fact that mice immunized with DNA-TRYP(-
Pam3CSK4)+MVA-TRYP exhibit enhanced levels of memory T
cells together with an overall reduction in IL-13 and increased
IFNc production in comparison to DNA-TRYP+MVA-TRYP or
DNA-TRYP vaccinated mice, we asked whether these responses
might be useful in directing protection against infection. Mice
were vaccinated as indicated above. Control mice were immu-
nized with control plasmid and control MVA. Six weeks after the
final immunization, all mice were infected with 5610
4 L. (V).
panamensis promastigotes and lesion development was monitored.
As shown in Figure 3A, mice immunized with DNA-
TRYP(Pam3CSK4)+MVA-TRYP exhibited significantly smaller
lesions when compared to control mice (control plasmid and
MVA) and all other vaccine groups. Furthermore, significantly
lower parasite burden levels were found at the both the site of
Figure 1. Up regulation of Th1 cytokines and down regulation of Th2 cytokines in DNA-TRYP(Pam)+MVA-TRYP immunization.
Twelve weeks after the final immunization, cells from individual spleens of immunized (DNA-TRYP+DNA-TRYP, DNA-TRYP+MVA-TRYP, DNA-
TRYP(Pam)+MVA-TRYP) and control mice (DNA-pVAX(Pam)+MVA-Luc) were re-stimulated in vitro with recombinant TRYP or SLA for 72 hours
followed by analysis of supernatants obtained for IFNc, granzyme B, IL-13 and IL-10. Data are representative of 2 experiments; n=3 mice/group.
Mean6SE. *p,0.05, **p,.005.
doi:10.1371/journal.pntd.0001204.g001
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www.plosntds.org 4 June 2011 | Volume 5 | Issue 6 | e1204Figure 2. TLR2 activation leads to increased CD4+ and CD8+ memory populations. CD4 and CD8 T cell memory responses to TRYP antigen
were examined 12 weeks after the MVA-TRYP boost A. Splenocytes from immunized and control groups of mice (3 mice/group) were CFSE labeled
followed by in vitro stimulation with TRYP protein for 3 days to track proliferation of antigen specific cells. CD4 – Vector or DNA-TRYP+DNA-TRYP or
DNA-TRYP+MVA-TRYP compared to DNA-TRYP(Pam)+MVA-TRYP is p,0.05. CD8 – Vector or DNA-TRYP+DNA-TRYP or DNA-TRYP+MVA-TRYP
compared to DNA-TRYP(Pam)+MVA-TRYP is p,0.009. B. The cytokine responses of memory CD4 and CD8 cells in TRYP(Pam)+MVA-TRYP immunized
mice (3 mice/group) were evaluated by FACS analysis of splenocytes stimulated in vitro with recombinant TRYP. Forward and side scatter were used
to determine lymphocytes followed by gating on CD4+ or CD8+ cells. C. Overall frequency of antigen specific CD4 and CD8 cells producing IFNc or IL-
13 in different groups of vaccinated mice as determined by FACS analysis. Data are representative of two independent experiments. n=3 mice/
group.
doi:10.1371/journal.pntd.0001204.g002
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TRYP vaccinated mice, when compared to control immunized
mice (574-fold) or mice immunized with DNA-TRYP (267-fold) or
TRYP+MVA-TRYP (314-fold) (Figure 3B). Consistent with
previously reported results [19], DNA-TRYP immunization alone
failed to protect against L.(V). panamensis infection. Notably,
heterologous prime-boost vaccination alone also does not induce
protection as seen from lesion size measurement and parasite load
at the site of infection. However, parasite numbers in DLN in
DNA-TRYP+MVA-TRYP immunized mice are significantly
lower (11-fold) than that of control mice. Therefore Pam3CSK4
plays a critical role in achieving protection against murine L.(V).
panamensis infection using heterologous prime-boost vaccination.
Negative role of IL-13 or IL-10 in protection against L. (V.)
panamensis infection in mice immunized with DNA-
TRYP(Pam3CSK4)+MVA-TRYP
To evaluate mechanisms underlying the protection selectively
induced by DNA-TRYP(Pam3CSK4)+MVA-TRYP immuniza-
tion, the immune responses in DLN cells from the L.(V). panamensis
infected mice (control and immunized) were examined. In the
control group of mice, as found for chronic infection with L. (V.)
panamensis a mixed cytokine response was observed (IFN, IL-13,
IL-10). This demonstrated an ongoing inflammatory-anti-inflam-
matory immune response concomitant with parasite persistence.
In general, all TRYP vaccinated groups of mice produced lower
levels of cytokines than the control group of mice (vector).
Although a reduction in IFNc, as well as in IL-13 and IL-10 was
observed in the DLNs of L.(V).panamensis infected mice immunized
with DNA-TRYP(with or without Pam3CSK4)+MVA-TRYP in
comparison to control mice (Table 1), the predominant effect was
on the levels of IL-13 and IL-10. Interestingly the levels of IFNc
observed for vaccine groups boosted with MVA-TRYP (DNA-
TRYP and DNA-TRYP(Pam3CSK4)) were comparable. Howev-
er, reductions in both IL-13 and IL-10 occurred for the mice
vaccinated with DNA-TRYP(6Pam3CSK4)+MVA-TRYP in
comparison to those receiving DNA-TRYP alone, with the
principal decrease being in IL-10 for the mice immunized with
DNA-TRYP(Pam3CSK4)+MVA-TRYP.
Although the infected vaccinated mice produced lower levels of
cytokines than the control mice, it is notable that the relative levels
of the cytokines differ between the various groups, with the highest
IFNc/IL-10 or IFNc/IL-13 ratios observed for the DNA-
TRYP(Pam3CSK4) +MVA-TRYP group of mice. The down-
regulation of IL-10 as well as IL-13 is consistent with the memory
responses observed prior to infectious challenge (Figures 1 and 2)
and suggests that lower levels of these cytokines are critical to
parasite containment. These results are consistent with the roles of
these cytokines in pathogenesis [22]. Further, these findings are
similar to vaccine studies of L. major utilizing MVA vaccination
[24] where IFNc/IL-10 was found to be predictive of protection.
CD8
+ T cells are critical to the protection induced by
TLR1/2 (TRYP (Pam3CSK4)) modulation of DNA priming
The cytokine responses clearly changed with the mode of
vaccination; however, it was unclear what the role of specific T cell
populations might be in this process. The IFNc responses and
memory populations of both CD4 and CD8 T cells appeared to
increase with TLR1/2 activation (Figure 2). To examine the
specific contribution of effector CD8 and CD4 T cells to
protection, vaccinated mice (DNA-TRYP(Pam3CSK4)+MVA-
TRYP) were immunodepleted immediately prior to infection with
L.(V.) panamensis. As seen in Figure 4A, CD8 T cell depletion
significantly reversed protection and lesion development. Intrigu-
ingly, although lesion development was still somewhat restrained
in the CD8 T cell depleted group in comparison to the vector
control group, the parasite burdens in these two groups were
comparable (Figure 4B), indicating no control on parasite growth
occurred in the absence of CD8 T cells. The importance of CD8 T
cells to protection is consistent with the heightened in vitro
memory CD8 T cell expansion in response to antigen observed
(Figure 2) of the mice primed with DNA-TRYP(Pam3CSK4) in
comparison to mice receiving DNA-TRYP alone.
Interestingly based upon lesion development, the DNA-
TRYP(Pam3CSK4)+MVA-TRYP immunized mice depleted of
CD4 T cells are significantly resistant to infection. These data are
confirmed by parasite burden levels at the site of infection
(Figure 4B), which indicate significantly lower levels of parasites in
the vaccinated mice deleted of CD4 T cells when compared to
DNA-TRYP(Pam3CSK4)+MVA-TRYP immunized mice. Over-
all, it appears that CD8 T cell effectors in the absence of CD4 T
cells can provide significant protection against L. (V.) panamensis
infection. Furthermore, CD4 T cell effector populations do not
appear to significantly contribute to protection in the vaccinated
mice.
Figure 3. TRYP(Pam3CSK4)-MVA-TRYP protects against L(V.)
panamensis infection. A. Lesion development in the control and
groups of TRYP-immunized mice infected with 5610
4L (V.) panamensis.
n=8/group For statistical significance comparison was made between
DNA-TRYP(PAM3CSK4)+MVA-TRYP immunized mice and other groups
of mice. B. Parasite burden at the site of infection and draining lymph
node were determined by limiting dilution analysis at 6 weeks after
infection. n=4/group, *=p,0.05, **=p,0.008. Results are represen-
tative of 2 independent experiments.
doi:10.1371/journal.pntd.0001204.g003
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groups of infected vaccinated mice indicated that the groups
of protected mice (DNA-TRYP(Pam3CSK4)+MVA-TRYP and
DNA-TRYP(Pam3CSK4)+MVA-TRYP–CD4 depleted) produ-
ced significantly lower levels of IFNc, IL-13 and IL-10 (Figure 5),
when compared to infected control mice. Mice immunized with
DNA-TRYP+MVA-TRYP and notably mice immunized with
DNA-TRYP(Pam3CSK4)+MVA-TRYP and depleted of CD8
cells had elevated levels of all three cytokines. Interestingly DNA-
TRYP(Pam3CSK4)+MVA-TRYP immunized mice depleted of
CD4 cells produced lower levels of IL-13 and IL-10 when
compared to DNA-TRYP(Pam3CSK4)+MVA-TRYP immunized
mice. However, no difference in IFNc levels was observed bet-
ween these two groups. Reduced levels of IL-10 and IL-13 have
been found to lead to control of L. (V.) panamensis infection [22].
Consequently, it appears that healing and resolution of
infection is dependent upon effector CD8 T cells; overall
activation of CD8 T cells results in lower levels of IL-13 and
IL-10 as well as IFNc produced in response to infection.
Interestingly, the depletion of CD4 T cells leads to a further
reduction of both IL-10 and IL-13, whereas no change in the
IFNc response occurs. Together, these data demonstrate the
essential role of CD8 cells in mediating protection induced by
DNA-TRYP(Pam3CSK4)+MVA-TRYP against L.(V.) panamensis
infection. Moreover, these results suggest that CD8 T cells may
perform this function through the regulation of IL-13 and IL-10
production. However, further experiments are required to
determine this point.
Discussion
The Leishmania (Viannia) subgenus is phylogenetically divergent
from other Leishmania [8,9,10]. Reflected in this is the fact that
infection by members of this subgenus generates a hyperinflam-
matory and mixed Th1/Th2 response (and high levels of IFNc)
that can fail to resolve [11,12,13,14,15]. Furthermore vaccination
against infection in the murine model has been challenging, as
approaches utilizing conserved antigens previously shown to
induce substantial protection against other Leishmania sp. have
failed to provide protection [19,21] implying that novel immuni-
zation strategies are required. Recent studies [20] indicate that
immunization with replication defective Leishmania can provide
partial protection against L. (V.) braziliensis infection; but the
protective mechanisms involved were not explored. Our results in
part are consistent with these studies, as neither DNA vaccination
alone nor heterologous prime-boost vaccination (DNA+MVA)
(using the conserved TRYP antigen) leads to significant protection
against L. (V.) panamensis infection/disease. Nonetheless, the prime-
boost modality has been shown to provide protection against
Table 1. Cytokine production of vaccinated mice 6 weeks post-infection with L.(V.) panamensis.
Groups IFNcpg/ml IL-13 pg/ml 1L-10 pg/ml Ratio IFNc/IL-13 Ratio IFNc/IL-10
Vector Control 7312642 71865.1 105766.1 10.2 6.9
DNA-TryP + DNA-TryP 5262630 37662.7 65663.8 14.0 8.0
DNA-TryP + MVA-TryP 4797628 17761.3* 38562.2* 27.2 12.4
DNA-TryP(Pam3CSK4) + MVA-TryP 4603627 15261.1*
+ 16060.9*
+ 30.2 28.9
Pooled DLN cells from immunized and control mice (n=4 mice) infected with L.(V.) panamensis were stimulated in vitro with SLA for 72 hours (duplicate `)a n d
supernatants were analyzed for indicated cytokines by ELISA. Mean6SD. Results are representative of 2 independent experiments.
*p,0.05 DNA-TryP+DNA-TryP vs DNA-TryP+MVA-TryP or DNA-TryP(Pam)+MVA-TryP;
+p,0.05 DNA-TryP+ MVA-TryP vs DNA-TryP(Pam)+MVA-TryP.
doi:10.1371/journal.pntd.0001204.t001
Figure 4. CD8 cells contribute to TLR1/2 mediated protection.
A. Lesion size (mean6SE) progression in L.(V).panamensis infected mice
that were protectively immunized with DNA-TRYP(Pam)+MVA-TRYP and
depleted of CD4 (-CD4) or CD8 cells (-CD8) prior to infection. ND,
indicates not depleted or intact vaccinated mice. Controls include mice
immunized vector plasmid and MVA. n=10 mice per group. * p,0.05
Vector vs. DNA-TRYP(Pam)+MVA-TRYP; + p,0.05 DNA-TRYP(-
Pam)+MVA-TRYP CD4 depleted vs. DNA-TRYP(Pam)+MVA-TRYP; ++
p,0.005 DNA-TRYP(Pam)+MVA-TRYP CD4 depleted vs. DNA-TRYP
(Pam)+MVA-TRYP; # p,0.005 Vector vs. DNA-TRYP(Pam)+MVA-TRYP
CD8 depleted. B. Parasite burden (mean6 SE) at the site of infection
was determined by limiting dilution assay at 8 weeks after infection.
(n=4 mice per group). * p,0.05.
doi:10.1371/journal.pntd.0001204.g004
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leishmaniasis, when DNA vaccination alone failed [42,43]. In this
report we demonstrate that significant protection against chronic
L. (V). panamensis infection can be achieved using a heterologous
prime-boost (DNA -MVA) modality using aTLR2/1 ligand
(Pam3CSK4) as the adjuvant and a single defined antigen, TRYP.
As expected in response to heterologous prime-boost vaccina-
tion, groups of mice boosted with MVA-TRYP produced high
levels of IFNc. However mice immunized with DNA-TRYP(-
Pam3CSK4) +MVA-TRYP produced higher levels of IFNc as
well as significantly reduced levels of IL-13 and IL-10 when
compared to mice immunized with DNA-TRYP+MVA-TRYP.
This effect of Pam3CSK4 is consistent with initial experiments
using the Pam3CSK4 adjuvant for DNA vaccination alone,
thereby indicating the striking capacity of Pam3CSK4 during
priming to down-regulate IL-13 and IL-10 responses, leading to a
Th1 biased immune response. Interestingly Pam3CSK4 has been
shown to induce a mixed cytokine response (IL-12, IL-10, TNFa)
in mouse bone marrow derived dendritic cells [44]. However
evidence indicates that during allergic inflammation, that
enhanced Th1 responses are observed [45] in response to
Pam3CSK4 stimulation. Consequently, the tissue site and context
(presence of other immunomodulators) can impact the effect of an
adjuvant on the developing immune response. Within the dermal
compartment (site of DNA vaccination) skin resident DCs [46,47]
are the probable target population of intradermally delivered
DNA-TRYP and Pam3CSK4 [48] and TLR9 (bacterial DNA-
CpG)/TLR2 activation. Costimulation (TLR, NOD or TCR of
NK-T cells [32,49,50]) of dendritic, macrophage, and early
responding cells may further cooperate and selectively drive/
amplify specific responses [44,51]. DNA immunization and
activation of TLR9 results in strong IL-12 production, leading
to a predominant Th1 immune response [52]. Interestingly, both
synergy and co-operation between TLR2 and TLR9 have been
observed in response to infection [51,53,54] resulting in height-
ened Th1-like responses. Joint TLR9 and TLR2 engagement has
also been shown to result in the production of MCP-1 and
synergistic production of RANTES [55], which would lead to
increased recruitment of macrophages/monocytes, T cells, and
dendritic cells [56]. This increased cellular recruitment could
potentially lead to enhanced T cell expansion, as observed herein
for both CD4+ and CD8+ T cells. Further, TLR2 receptors are
present on T cells and therefore TLR2 activation could also
modulate the developing adaptive immune response. TLR2
activation of Tregs has been shown to mitigate (at least temporally)
their suppressive quality [57,58,59], which could lead to increased
proliferation and expansion of antigen specific T effector cells.
CD8 T cell activation has been related to both healing and
pathogenesis in leishmaniasis (reviewed in [60]). In the human
immune response to Leishmania (Viannia) infection, studies implicate
CD8 T cells in disease resolution [61,62] as well as pathology
[63,64]. The variation in the observed effects found for CD8+ T
cells may reflect the functional heterogeneity of these cells
[65,66,67]. CD8 T cells have been shown to exert a curative
role in murine models of leishmaniasis, which has been attributed
to the production of IFNc [60,68,69,70] as well as a potential role
for perforin (CTL function)[71]. Further, other mediators
produced by CD8 T cells (granzymes, chemokines, cytokines)
may also contribute to the host defense. Although murine studies
have unambiguously demonstrated that CD8 cells participate in
vaccine-induced protection against infection [32,68,72] caused by
other Leishmania species, the contributions to host defense against
Leishmania (Viannia) have not been previously determined.
While both CD4 and CD8 T cell responses (memory and IFNc)
were increased in response to vaccination using TLR1/2,
protection was largely due to the CD8 T effector cell response,
as protection was reversed in mice depleted of CD8 cells, but not
upon CD4 cell depletion. These results differ from heterologous
Figure 5. Modulation of cytokine production in TRYP(Pam)+MVA-TRYP protectively vaccinated mice depleted of CD8 or CD8 T
cells. At 8 weeks post-infection with L.(V).panamensis, the IFNc, IL-13 or IL-10 responses were determined in DLNs of non-immunized and TRYP
immunized mice (n=4 per group). Cells from individual mice were pooled and then stimulated for 72 hours with SLA (in duplicate) and cytokine
levels determined as indicated in the Materials and Methods Section. Mean6SD. *p,0.05, ** p,0.005; -CD4, CD4 depleted; -CD8, CD8 depleted; ND –
Not Depleted.
doi:10.1371/journal.pntd.0001204.g005
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DNA priming [32], where CD4 T responses appeared responsible
for anti-leishmanial response [32]. The overall reason that CD8 T
cell were the primary effectors of protection is not clear and may
be due to the antigen and/or adjuvant utilized for these studies as
well as the specific modes of action/effector mechanisms of the
CD8 T cells elicited. It is of interest that TryP has been found in
the leishmanial exosome [73,74]. Consequently, it may be that the
preferential mode of action found by CD8 T (in spite of a clear
CD4 T cell response) is biased by the release and subcellular
localization of this antigen during infection. However, further
work is required to determine this point and the potential of
exosomal antigens as CD8 vaccine candidates. Alternately, other
studies employing Pam3CSK4 as an adjuvant clearly demonstrate
its ability to enhance CD8 responses [75,76,77]. Our findings are
consistent with these observations. Long-term memory (12 weeks
after the vaccinia boost) development in immunized mice was
heightened in mice receiving Pam3CSK4, with a marked
expansion of the CD8 T cell population. Although the precise
mechanism by which Pam3CSK4 augments the CD8 T cell
response is not completely understood, Pam3CSK4 has been
shown to enhance dendritic cell cross presentation to CD8 T cells
[78]. Further, reports show that Pam3CSK4 engages TLR2 on
CD8 cells [79], prolonging their survival and increasing
proliferation that may contribute to increased frequency of
antigen-specific CD8 cells. Furthermore, TLR2 engagement on
DC subsets has been reported to lead to enhanced trafficking of
these cells to the draining lymph nodes [80,81], which would
further contribute to the development of enhanced CD8 response.
We have recently shown a role for IL-13 and IL-10 in
determining disease progression in the murine model of L.(V).pa-
namensis [22] infection. Results presented here are consistent with
this finding and further demonstrate a correlation between
parasite load and levels of these cytokines. Unexpectedly, depletion
of effector CD4 T cells did not appear to influence resistance. CD4
cells appear to be a source of IL-13 and IL-10 in the vaccinated
mice, as observed in FACS analyses and the fact that CD4 cellular
depletion results in further reduction of IL-13 and IL-10. In
contrast, CD8 T effector cell depletion reversed protection and led
to the production of higher levels of both IL-10 and IL-13.
Overall, the consequence of CD8 cell activation was to modulate
protection by limiting IL-10 and IL-13. CD8 T cells have been
shown to modulate Th2 CD4 T cell function both through direct
T-T interaction [82] or the indirect consequence of CD8
activation on other cell populations [83,84]. Similarly CD8 T cell
have been observed in the case of L. major [69] to direct increase
levels of CD4-IFNc production. Our results are consistent with the
possibility that CD8 T cells are involved in the immune
‘‘deviation’’ of CD4 T cells and that this is involved in the
development of protection against infection. However, further
work is required to determine this point. An understanding of the
mechanisms by which CD8 T cells promote host defense and
mediate protection is of obvious interest for vaccine development
against L. (Viannia).
This is the first report of successful protection against L.(V.)
panamensis using a single antigen. By utilizing a TLR2 agonist
(Pam3CSK4) in a heterologous prime boost immunization method
we have demonstrated protection against L.(V.) panamensis in a
murine model. This protection was achieved specifically through
the expansion of antigen-specific effector CD8 T cells. These
findings suggest that the modulation of TLR1/2 signaling may
dramatically improve the efficacy of DNA-based vaccine modal-
ities, especially where CD8 T cell activation is critical, thereby
contributing to effective and affordable anti parasitic vaccines.
Supporting Information
Figure S1 Adjuvant Modification of Cytokine Response
to p36 (LACK) Antigen. A) Mice (n=3 per group) were
immunized twice intradermally at biweekly intervals with either
PBS (Control) or DNAp36 in combination with a-GalCer, CpG,
LPS, MALP-2 or Pam3CSK4. IFN-c and IL-10 production by
splenocytes from immunized mice (stimulated in vitro with
recombinant p36 three to four weeks after the last immunization)
was determined. B and C) Mice were immunized as above using
DNAp36 together with a-GalCer or/and Pam3CSK4. IFN-c, IL-
10 and IL-13 production were evaluated 3 to 4 weeks after the
final immunization. Control mice received PBS alone(n=3 per
group). Results are representative of 2 experiments. Mean 6 SE.
The values above the bars indicate the IFN-c/IL-10 or IFN-c/IL-
13 ratio for the specific adjuvant.
(TIF)
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